International Wex Technologies Inc. ('Wex'or the 'Company') is pleased to announce today that it has filed a Clinical Trial Application (CTA) with Health Canada for its pivotal Phase IIb/III clinical study. This study will be a randomized, multicentre, double-blind, placebo-controlled study of the efficacy and safety of subcutaneous tetrodotoxin (Tectin(TM)) for moderate to severe cancer-related pain.
The filing of this CTA is an important achievement for the Company, representing a significant step forward not only for Wex's overall strategic plan, but also for the development of its Tectin(TM) drug line.
This study will include several new approaches to the development of Tectin(TM). As intramuscular injection is inconvenient for severe cancer pain patients, subcutaneous injections will now be used. Recruitment will be open to both hospitalized and outpatients including subjects suffering from moderate pain. Wex is confident that these new criteria will enhance enrolment, thus allowing the study to be completed in a shorter time frame.
International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.
Per: Donna Shum, Corporate Secretary
International Wex Technologies Inc. Gordon Stanley Corporate Communications (604) 683-8880 or 1-800-722-7549 Email: wex@wextech.ca Website: wextech.ca |
